Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 80Years
All Genders
ID05455034

Single-cell Sequencing of Bronchoalveolar Lavage Fluid to Guide Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis

Led by Xinqiao Hospital of Chongqing · Updated on 2025-07-14

40

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are exploring radiation pneumonitis and immune checkpoint inhibitor pneumonitis in patients using single-cell sequencing of bronchoalveolar lavage fluid. The goal is to understand how these conditions develop and find ways to prevent them. This study uses a new technology to guide treatment based on findings from single-cell sequencing and treatment guidelines. Participants receive single-cell sequencing tests before treatment. Based on the results, patients are treated specifically for radiation pneumonitis or immune checkpoint inhibitor pneumonitis according to recommended guidelines. This study includes two groups, each receiving treatment tailored to their respective pneumonitis type. During the study, patients undergo bronchoalveolar lavage fluid sampling and single-cell sequencing before treatment. Researchers will monitor response rates over an 8-week period after treatment begins. Participants are evaluated regularly to track treatment effects and safety, with the study lasting up to the end date in December 2025.

CONDITIONS

Brief Title

Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent and able to comply with study protocol
  • Diagnosed with non-small cell lung cancer and radiation pneumonitis or immune checkpoint inhibitor pneumonitis after confirmed radiotherapy or immunocheckpoint inhibitor treatment
  • Age 18 to less than 75 years
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 3
  • No contraindications to bronchoalveolar lavage
Not Eligible

You will not qualify if you...

  • Poor compliance or violation of study rules
  • Liver or kidney dysfunction such as recent heart attack, angina, or significantly increased liver enzymes
  • Required systemic corticosteroids or immunosuppressive drugs within 14 days before enrollment
  • Severe infection or hospitalization due to infection within 4 weeks before enrollment
  • Severe chronic or active infections needing systemic antibiotics within 14 days before enrollment
  • Untreated chronic hepatitis B with high viral load or active hepatitis C infection
  • Known HIV infection
  • Participation in another clinical trial or investigational drug use within 28 days before enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 8 weeks

Participants undergo single-cell sequencing of bronchoalveolar lavage fluid before receiving treatment for radiation pneumonitis or immune checkpoint inhibitor pneumonitis based on sequencing results and treatment guidelines.

1 baseline visit and multiple treatment visits as per clinical guideline

Trial Site Locations

Total: 1 location

1

Xinqiao Hospital

Chongqing, Chongqing Municipality, China, 400037

Actively Recruiting

Loading map...

Research Team

J

Jianguo Sun, doctor

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial